China Has ‘Cornered the Market’ on Pharmaceutical Ingredients, Jeopardizing US National Security: Rep. Harshbarger

China Has ‘Cornered the Market’ on Pharmaceutical Ingredients, Jeopardizing US National Security: Rep. Harshbarger
Rep. Diana Harshbarger (R-Tenn.) and other House Republicans participate in a press conference to discuss the Democrats' spending package at the U.S. Capitol on Nov. 2, 2021. Allison Shelley/Getty Images
Updated:
0:00

A Republican lawmaker says pharmaceuticals acquired from China are nothing less than medication acquired from the nation’s enemy. She’s fearful that supply chains could be leveraged against the United States.

Earlier this year, Rep. Mike Gallagher (R-Wis.) and colleagues introduced the “Protecting our Pharmaceutical Supply Chain from China Act of 2022” (H.R.7121). The legislation aims “to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in the People’s Republic of China, and for other purposes.”
Related Topics